Dyskinesia News and Research

RSS
Young Researcher's Meeting on Primary Ciliary Dyskinesia to be held in Bern, Switzerland

Young Researcher's Meeting on Primary Ciliary Dyskinesia to be held in Bern, Switzerland

FDA approves RYTARY for Parkinson's disease treatment

FDA approves RYTARY for Parkinson's disease treatment

Brandeis University researchers capture highest resolution images of cilia ever

Brandeis University researchers capture highest resolution images of cilia ever

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Levodopa dose linked to malnutrition risk in Parkinson’s disease

Levodopa dose linked to malnutrition risk in Parkinson’s disease

Zebrafish may hold key to unlocking a leading cause of respiratory diseases

Zebrafish may hold key to unlocking a leading cause of respiratory diseases

Research to help patients suffering from severe spinal cord injuries

Research to help patients suffering from severe spinal cord injuries

Study: Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

Study: Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

Sleep problems in PD patients can worsen in later stages of disease

Sleep problems in PD patients can worsen in later stages of disease

Low accuracy of clinical diagnosis for early Parkinson’s disease

Low accuracy of clinical diagnosis for early Parkinson’s disease

Little efficacy difference between old and new antipsychotics

Little efficacy difference between old and new antipsychotics

Presynaptic dopaminergic lesion predicts drug-induced dyskinesia

Presynaptic dopaminergic lesion predicts drug-induced dyskinesia

Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

Civitas reports positive results from CVT-301 Phase 2b trial for treatment of Parkinson's disease

Civitas reports positive results from CVT-301 Phase 2b trial for treatment of Parkinson's disease

New insights into possible common links between neurodegenerative diseases

New insights into possible common links between neurodegenerative diseases

GLNT receives allowance of patent for Parkinson's disease monitoring technology

GLNT receives allowance of patent for Parkinson's disease monitoring technology

Great Lakes NeuroTechnologies receives another patent for Parkinson’s disease monitoring technology

Great Lakes NeuroTechnologies receives another patent for Parkinson’s disease monitoring technology

More antipsychotic medications prescribed to children and adolescents in Germany

More antipsychotic medications prescribed to children and adolescents in Germany

‘Limit diagnostic investigations’ in children with recurrent CAP

‘Limit diagnostic investigations’ in children with recurrent CAP

Adamas Pharmaceuticals reports positive results from ADS-5102 Phase 2/3 EASED clinical trial

Adamas Pharmaceuticals reports positive results from ADS-5102 Phase 2/3 EASED clinical trial